VIR Stock Chart & Stats
$146.01
-$12.00(-7.59%)
―
--
Day’s Range― - ―
52-Week Range$138.61 - $189.19
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
$25.62B
Enterprise Value$937.67
Total Cash (Recent Filing)$472.36M
Total Debt (Recent Filing)$95.58M
Price to Earnings (P/E)―
Beta-0.07
Next Earnings
Aug 05, 2026EPS Estimate
5.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.13
Shares Outstanding168,651,980
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.09
Price to Sales (P/S)12.18
P/FCF Ratio-2.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$375.19Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Vir Biotechnology News
VIR FAQ
What was Vir Biotechnology, Inc.’s price range in the past 12 months?
Vir Biotechnology, Inc. lowest stock price was $138.61 and its highest was $189.19 in the past 12 months.
What is Vir Biotechnology, Inc.’s market cap?
Vir Biotechnology, Inc.’s market cap is $25.62B.
When is Vir Biotechnology, Inc.’s upcoming earnings report date?
Vir Biotechnology, Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 10 days.
How were Vir Biotechnology, Inc.’s earnings last quarter?
Vir Biotechnology, Inc. released its earnings results on May 06, 2026. The company reported -$14.883 earnings per share for the quarter, missing the consensus estimate of -$1.681 by -$13.202.
Is Vir Biotechnology, Inc. overvalued?
According to Wall Street analysts Vir Biotechnology, Inc.’s price is currently Undervalued.
Does Vir Biotechnology, Inc. pay dividends?
Vir Biotechnology, Inc. does not currently pay dividends.
What is Vir Biotechnology, Inc.’s EPS estimate?
Vir Biotechnology, Inc.’s EPS estimate is 5.83.
How many shares outstanding does Vir Biotechnology, Inc. have?
Vir Biotechnology, Inc. has 168,651,980 shares outstanding.
What happened to Vir Biotechnology, Inc.’s price movement after its last earnings report?
Vir Biotechnology, Inc. reported an EPS of -$14.883 in its last earnings report, missing expectations of -$1.681. Following the earnings report the stock price went down -9.841%.
Which hedge fund is a major shareholder of Vir Biotechnology, Inc.?
Currently, no hedge funds are holding shares in MX:VIR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vir Biotechnology Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$375.19 (― Downside)
$375.19 (― Downside)
Blogger Sentiment
Bullish
MX:VIR Sentiment 70%
Sector Average 65%
Sector Average 65%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
59.65%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-21.57%
Trailing 12-Months
Company Description
Vir Biotechnology, Inc.
Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.
VIR Stock 12 Month Forecast
Average Price Target
$375.19